Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03205072 · ClinicalTrials.gov registry record
POCS in Liver Transplantation Patients
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 42
- Enrollment target
NCT03205072: Completed study, sponsored by Boston Scientific Corporation.
NCT03205072 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03205072 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
A prospective, multi-center, non-randomized, observational, consecutive case series, which will compare Endoscopic Retrograde Cholangiopancreatoscopy (ERCP) and cholangioscopy with Spy Glass Digital System (DS) procedure at 5-10 centers.
Primary Outcome
To evaluate the impact of the addition of POCS to same setting ERCP on the recommended management of post-liver transplantation biliary complications.
Interventions
- DEVICE Spy Glass DS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-01-25 |
| Est. Completion | 2022-03-24 |
What the finished NCT03205072 record still lists
NCT03205072 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Spy Glass DS is the first listed.
NCT03205072 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03205072 about?
NCT03205072 is a clinical study titled "POCS in Liver Transplantation Patients". A prospective, multi-center, non-randomized, observational, consecutive case series, which will compare Endoscopic Retrograde Cholangiopancreatoscopy (ERCP) and cholangioscopy with Spy Glass Digital System (DS) procedure at 5-10 centers.
What is the current status of trial NCT03205072?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2018-01-25. Estimated completion is 2022-03-24.
What interventions are being tested in trial NCT03205072?
The interventions under investigation include: Spy Glass DS (DEVICE).
Who is sponsoring clinical trial NCT03205072?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI